Body Pharm CJC-1295 + Ipamorelin 20mg

Body Pharm's 20 mg pen brings together a DAC-modified GHRH analogue (CJC-1295) and a selective agonist of GHS-R1a (ipamorelin) in a single pre-filled research format, which is delivered with batch traceability. CJC-1295 with DAC binds to the GHRH receptor on somatotroph cells and drives a sustained release of GH; the albumin conjugate extends the plasma half-life to 6–8 days. Ipamorelin activates the ghrelin receptor (GHS-R1a) with no measurable rise in either cortisol or prolactin in the published work in rodents. Combining the two of them in a single pen makes it possible to model the pulsatile dynamics of GH from a single 3 ml cartridge, because the two compounds activate distinct signalling pathways that do not share a mechanism of desensitisation. The dial sets the dose directly in milligrams. The masses of the components, the HPLC purity values and the storage parameters are confirmed against the batch-specific certificate of analysis that accompanies every unit, and they are not inferred from category norms.

CJC-1295 + ipamorelin pen: what you need to know

• CJC-1295 + ipamorelin activates two distinct somatotroph receptors (GHRH-R and GHS-R1a) with no overlapping desensitisation, and it produces a synergistic release of GH in the published models in rodents and primates
• The DAC group extends the half-life of CJC-1295 to 6–8 days; ipamorelin contributes selective agonism of GHS-R1a with no side effects on either cortisol or prolactin
• The pre-filled pen carries the two peptides co-formulated in a 3 ml cartridge and the dial sets the dose directly in milligrams: the figure dialled is the dose of each peptide, not the sum
• The reference scheme with DAC is around 100 mcg of each peptide, once a day, in the evening
• Dialling 0.1 mg delivers 0.1 mg of CJC-1295 and 0.1 mg of ipamorelin, 0.2 mg of blend per injection, so that the 20 mg in the pen yield 100 doses
• Every batch is delivered with a certificate of analysis that is linked to the batch number printed on the box, which makes it possible to check the purity and the origin directly
• Shipping within Spain (3–5 working days) avoids the customs delays and the long transit times that are the norm with orders placed abroad

What is CJC-1295 + ipamorelin?

CJC-1295 + ipamorelin is a research-peptide combination made up of a DAC-modified GHRH analogue (CJC-1295) and a selective agonist of the ghrelin receptor (ipamorelin). The two compounds activate distinct somatotroph receptors (GHRH-R and GHS-R1a) and produce an additive release of GH in the published models in rodents and primates, without the side effects on cortisol or prolactin that were seen with the earlier GHRPs, because they couple to different cascades of intracellular signalling.

CJC-1295 with DAC (Drug Affinity Complex) is a tetrasubstituted analogue of GHRH(1–29) that binds covalently to circulating albumin and extends its plasma half-life to around 6–8 days, as was characterised by Teichman et al. (2006, JCEM) [1]. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that was first described by Raun et al. (1998, Eur J Endocrinol) as a GHS-R1a agonist with a GH-releasing potency comparable to that of GHRP-6, but without the rise in ACTH, cortisol or prolactin that limits the other secretagogues [2].

Pairing them in a single pen takes advantage of desensitisation pathways that do not overlap: GHRH-R signals via Gαs/cAMP, whereas GHS-R1a couples to Gαq/PLC, so that down-regulation of the receptor on one axis does not attenuate the other in research models that involve repeated dosing. For the dosing methodology after purchase, see the complete CJC-1295 + ipamorelin dosing protocol; for a direct mechanistic contrast, see CJC-1295 vs. ipamorelin: comparing the peptides separately.

Mechanism: how the combination acts at receptor level

CJC-1295 with DAC is a long-acting GHRH analogue (half-life of around 6–8 days) that increases the amplitude of GH pulses without abolishing their rhythm; ipamorelin is a selective ghrelin-receptor agonist that triggers an additional pulse without raising cortisol or prolactin [1][2]. GHRH primes the somatotroph and the ghrelin mimetic fires it: the sum is greater than either one of them on its own. The complete mechanism and the human trials are in what is CJC-1295 + ipamorelin and in CJC-1295 vs. ipamorelin.

Why a 20 mg combination pen for research?

A pre-filled 20 mg combination pen reduces the variability of peptide research to a single figure that can be recorded per administration. The pen is delivered ready to dose, with CJC-1295 with DAC and ipamorelin co-formulated in a single sealed 3 ml cartridge. The dial sets the dose directly in milligrams and the mechanism of the device delivers it, so that the quantity that is injected is a property of the device and not of the technique of the operator.

For comparative pharmacology, molar matching matters more than matching by mass does. Body Pharm formulates the 20 mg combination in such a way that GHRH-R and GHS-R1a are co-stimulated in the model with a receptor occupancy that is functionally equivalent. The exact split of the components is printed on the batch CoA that accompanies every pen and is not inferred from the label. Anyone who is carrying out dose-response work should go directly to the molar values on the CoA when calculating the nmol/kg administered.

One cartridge for the two peptides

The two compounds are co-formulated in the same cartridge, so that a single injection covers both of the receptor arms and a single figure dialled on the dial describes the complete administration: that figure is the dose of each peptide, exactly as it is with the BPC-157 + TB-500 pen. The cartridge stays sealed inside the device for the entire dosing window, so that a study lasting several weeks is covered without the primary packaging being reopened. For dose and frequency plans, see the complete CJC-1295 + ipamorelin dosing protocol; for the mechanistic rationale for pairing them rather than using the peptides in isolation, see CJC-1295 vs. ipamorelin: comparing the peptides separately.

Body Pharm CJC-1295 + Ipamorelin 20 mg: product specification

Body Pharm's 20 mg combination is delivered in the form of a sealed subcutaneous multi-dose pen with a batch-referenced certificate of analysis, with tracked shipping for a flat shipping fee within Spain (3–5 working days) and with a 14-day right of return for units that are unused and unopened. The specification below corresponds to Body Pharm's current product data as of 2026. The split at component level and the exact purity by HPLC are confirmed against the batch CoA that is included in the packaging, and they are not inferred from the label.

Solely for research and analytical purposes. Not for use in people or in animals, not for diagnostic procedures, and not for food or cosmetic formulations. Anyone who is moving on to the calculation of doses should cross-check the molar values on the CoA against the complete CJC-1295 + ipamorelin dosing protocol.

Quality, origin and batch traceability

Every Body Pharm CJC-1295 + ipamorelin pen is filled, sealed and dose-validated before it is shipped, with a batch number printed on the outer packaging that refers directly to a certificate of analysis for that particular batch. That batch number is the single reference with which a research team checks the identity, the purity and the origin against the CoA included in the packaging. The analytical confirmation rests on HPLC as a minimum, supplemented by mass spectrometry wherever the identity of the peptide needs an orthogonal confirmation. The exact purity threshold and the readout of the method are stated on the batch sheet and are not generalised across the whole of the inventory.

Full traceability means three concrete things: the CoA refers to the same batch number as the box does, the date of synthesis is documented, and the analytical results are tied to that specific fill and not to a generic product specification. Grey-market suppliers routinely ship with no CoA at all, or they attach a generic one that is not linked to the unit in question, so that it is impossible to check what has actually been injected into the research model. Anyone with doubts about the integrity of the supply chain should check the batch number against the published CoA before using the product.

Shipping within Spain (3–5 working days, plain packaging) avoids two sources of error that are common with orders placed abroad: customs delays, which lengthen the transit considerably, and thermal exposure that cannot be verified in freight from third countries. For anyone who is planning a study window, that counts for more than the list price does, because long and uncontrolled transits can affect the stability of the peptide before the pen reaches the laboratory. The next step in the procedure is to cross-check the molar values on the CoA against the complete CJC-1295 + ipamorelin dosing protocol, or to review CJC-1295 vs. ipamorelin: comparing the peptides separately before finalising the rationale for the combination.

Dosing protocols for research with CJC-1295 + ipamorelin

The reference scheme is around 100 mcg of each peptide, once a day and in the evening, which is equivalent to dialling 0.1 mg on the dial; at that figure the pen yields 100 doses. The DAC is long-acting, so there are no multiple doses per day and no fasting windows. The cycle calendar and the administration notes are in how to dose CJC-1295 + ipamorelin.

CJC-1295 vs. ipamorelin: separate use versus combined use

The combination is directed at two distinct receptor pathways at the same time, which is why most of the secretagogue work in rodents published after 2010 uses the pairing rather than one of the peptides on its own. CJC-1295 with DAC binds to GHRH-R on somatotroph cells and provides a sustained stimulation of the GHRH axis over a period of days, but it depends on the endogenous ghrelin tone for the stimulus on GHS-R1a. Ipamorelin supplies that agonism of GHS-R1a selectively, with no measurable effect on cortisol or prolactin in the original characterisation by Raun et al. [2], but its plasma half-life is a short one (around 2 hours).

The pairing makes it possible to keep the GHRH-R signal elevated while the GHS-R1a pulse is administered according to the schedule of the research team rather than according to the circadian ghrelin rhythm of the model. The published work in rodents describes synergy in the combination, although to date no peer-reviewed in vivo study has been published that isolates Body Pharm's specific pen formulation against its components. Anyone who is comparing the combination with single-agent protocols should turn to the complete mechanistic comparison before finalising the protocol.

The complete mechanistic reasoning, with the receptor kinetics and the pulse-amplitude data, is in the separate-peptide comparison CJC-1295 vs. ipamorelin.

Ordering, delivery and returns for research buyers

All orders are sent with tracking for a flat shipping fee within Spain, in plain, unprinted outer packaging, with a usual delivery window of 3–5 working days.

Items that are unused and unopened can be returned within the 14 days following receipt for a refund. Pens that have been used or opened cannot be returned, for reasons of sterility and of chain of custody as they apply to the handling of research chemicals. Tracking numbers are assigned at the time of dispatch and they are visible in your account.

If the 20 mg combination pen shows as unavailable, sign up by way of the waitlist on the product page. You will receive a single email when the next batch released by quality control becomes available, together with the reference of the batch, so that the purchasing department can cross-check it against the published CoA before placing a new order.

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC (Drug Affinity Complex) carries a maleimide linker that binds covalently to serum albumin, extends the plasma half-life to around 6–8 days and produces a sustained signal at the GHRH receptor. CJC-1295 without DAC (also known as Mod GRF 1-29) does not have that linker and degrades in around 30 minutes, which produces a sharper signal that is tied to the pulse. Body Pharm's 20 mg pen uses the DAC-modified analogue in order to maintain a stable GHRH tone between the GHS-R1a pulses that are driven by ipamorelin.

Can I buy CJC-1295 + ipamorelin in Spain for research purposes?

Body Pharm supplies CJC-1295 and ipamorelin as research chemicals solely for in vitro and non-human laboratory purposes. They are not authorised as medicines for use in people. Buyers should check the legal status that is in force at the time of purchase and make sure that they have institutional approval for the research use they intend.

How should the pen be stored?

Keep the pen at between 2 and 8 °C and protected from light. While it is unopened, it keeps for 24 months. Once it has been punctured for the first time, use it within a period of 12 months. If you do not have a fridge available, the pen will tolerate up to 30 days at room temperature, with a maximum of 30 °C. Let it come up to room temperature before injecting and do not freeze it. Discard any pen that shows cloudiness or particles.

What purity standard does Body Pharm use?

Body Pharm releases every batch at an HPLC purity of ≥ 98%, with mass confirmation by LC-MS and endotoxin screening. The batch-specific CoA is published for the lot number that is printed on the pen, so that the purchasing department can cross-check it before accepting the delivery.

How is CJC-1295 + ipamorelin shipped?

All orders are sent with tracking for a flat shipping fee within Spain.

Next steps

Add the pen to your cart above, or read the complete CJC-1295 + ipamorelin dosing protocol before you order. If you are still comparing the combination with the use of a single agent, turn to CJC-1295 vs. ipamorelin: comparing the peptides separately in order to finalise the rationale for your protocol.

Sources

1. Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. J Clin Endocrinol Metab. 2006. pubmed.ncbi.nlm.nih.gov/16352683
2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. pubmed.ncbi.nlm.nih.gov/9849822